ZEOX · Zeo ScientifiX, Inc.
Substantial doubt about the company's ability to continue as a going concern.
“As of April 30, 2026, based on the factors described above, the Company concluded that there was substantial doubt about its ability to continue to operate as a going concern for the 12 months following the issuance of these financial statements. In addition, the Company's independent registered public accounting firm, in its report on the Company's October 31, 2025 financial statements, has expressed substantial doubt about the Company's ability to continue as a going concern.”View the 10-Q filed Jun 15, 2026
One customer — 14.2% of revenue (the six months ended April 30, 2026)
“During the six months ended April 30, 2026, the Company sold products and services totaling approximately $571,000 (14.2%) to a large medical practice group and distributor”
One customer — 12.7% of revenue (the six months ended April 30, 2026)
“and approximately $511,000 (12.7%) to another large medical practice group and distributor.”
One customer — 15.2% of revenue (the six months ended April 30, 2025)
“$341,000 (15.2%)”
One customer — 12.1% of revenue (the six months ended April 30, 2025)
“During the six months ended April 30, 2025, the Company sold products and services totaling approximately $270,000 (12.1%) to a large distributor”
One customer — 10.2% of revenue (the six months ended April 30, 2025)
“and $228,000 (10.2%) to two individual medical practices.”
Price & Indicators
Up next
Metrics snapshot
Useful current figures from the complete screener profile.
Quarterly results
* Q4 derived as the full year minus Q1 to Q3.
Equibles Rating
blended score · not investment adviceBlended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders Strong SellIllustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
Earlier KPI extraction records exist, but do not meet the current evidence-completeness requirements. No current verified series is available. Earlier figures remain withheld until revalidated; this is not evidence that the company reports no KPIs.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
ZEOX
this stock
Zeo ScientifiX, Inc.
|
$7.16M | -67.9% | +12.5% | — | 0.0% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$130.07B | +13.5% | +46.2% | 29.9 | 1.8% |
|
MRNA
Moderna, Inc.
|
$90.58B | +720.9% | +4.3% | — | 7.7% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$80.51B | +4.6% | +20.8% | 19.4 | 2.1% |
|
CSLLY
Csl Ltd
|
$66.34B | — | — | — | 0.0% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionPerformance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| ZEOX | -24.1% | -37.9% | -53.0% | -29.8% | -67.9% |
| SPY | -1.2% | -0.6% | +8.1% | +0.8% | +12.8% |
| vs SPY | -22.9% | -37.3% | -61.1% | -30.7% | -80.7% |